Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.80 |
| ▸ | MMP1 | P03956 | 10/20 | 0.80 |
| ▸ | MMP9 | P14780 | 7/20 | 0.80 |
| ▸ | MMP3 | P08254 | 7/20 | 0.80 |
| ▸ | MMP8 | P22894 | 5/20 | 0.80 |
| ▸ | MMP7 | P09237 | 3/20 | 0.80 |
| ▸ | FCER2 | P06734 | 1/20 | 0.80 |
| ▸ | MMP12 | P39900 | 1/20 | 0.65 |
| ▸ | MMP13 | P45452 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7408183 | 0.90 | MMP2 (0.66) | MMP2MMP1MMP9MMP3MMP8 | |
| SCHEMBL5502507 | 0.89 | MMP2 (1.00) | MMP2MMP1MMP9MMP3MMP8 | |
| SCHEMBL4633155 | 0.88 | MMP2 (0.81) | MMP2MMP1MMP9MMP3MMP8 | |
| SCHEMBL27547968 | 0.88 | MMP2 (0.81) | MMP2MMP1MMP9MMP3MMP8 | |
| SCHEMBL5556655 | 0.87 | MMP2 (0.81) | MMP2MMP1MMP9MMP3MMP8 | |
| SCHEMBL5558802 | 0.87 | MMP2 (0.81) | MMP2MMP1MMP9MMP3MMP8 | |
| SCHEMBL5556662 | 0.87 | MMP2 (0.81) | MMP2MMP1MMP9MMP3MMP8 | |
| SCHEMBL5558806 | 0.87 | MMP2 (0.81) | MMP2MMP1MMP9MMP3MMP8 | |
| SCHEMBL7270500 | 0.87 | MMP1 (1.00) | MMP2MMP1MMP9MMP3MMP8 | |
| SCHEMBL7612909 | 0.86 | MMP1 (0.71) | MMP2MMP1MMP9MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348017-B2 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO., LTD. (JP) | 2008-03-25 | — | — | US | disclosed |
| US-20040236111-A1 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422224-A1 | DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN | Shiseido Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236111-A1 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | MMP1, MMP2, MMP3 | MMP2 2/4885MMP1 1/4885MMP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.